Free Trial
→ Why I went to Mount Rushmore (From Stansberry Research) (Ad)tc pixel
NASDAQ:MLTX

MoonLake Immunotherapeutics Q3 2026 Earnings Date & Estimates

MoonLake Immunotherapeutics logo
$10.82 +0.24 (+2.27%)
Closing price 10/9/2026 04:00 PM Eastern
Extended Trading
$10.93 +0.11 (+1.02%)
As of 10/9/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

MoonLake Immunotherapeutics is expected to report Q3 2026 earnings on Wednesday, November 4, 2026, before market opens. The conference call is scheduled for November 5, 2026 at 12:30 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
Before Market Opens
Conference Call Date
Conference Call
12:30 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from MoonLake Immunotherapeutics in Q3 2026

MoonLake Immunotherapeutics is expected to post earnings of -$0.77 per share. In the same quarter a year earlier MoonLake Immunotherapeutics reported -$1.10 per share. MoonLake Immunotherapeutics last reported on August 10, 2026, posting -$0.84 per share and beating the -$0.9086 consensus estimate. MoonLake Immunotherapeutics has beaten the consensus EPS estimate in 2 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.77
Prior-Year EPS
-$1.10

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.84 (Beat by +$0.0686)
EPS Beat Rate
2 of last 8 quarters

Prepare for the Q3 2026 Call

MoonLake Immunotherapeutics Q3 2026 Earnings FAQ

MoonLake Immunotherapeutics (NASDAQ:MLTX) is estimated to report Q3 2026 earnings on Wednesday, November 4, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it.

MoonLake Immunotherapeutics' Q3 2026 earnings conference call is scheduled for Thursday, November 5, 2026 at 12:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect MoonLake Immunotherapeutics to post earnings of -$0.77 per share for Q3 2026.

MoonLake Immunotherapeutics Earnings Headlines

MoonLake Immunotherapeutics (MLTX) Receives a Rating Update from a Top Analyst
October 8 at 1:31 PM  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/MLTX-Q/pressreleases/4933773/moonlake-immunotherapeutics-mltx-receives-a-rating-update-from-a-top-analyst/
MoonLake Immunotherapeutics (NASDAQ:MLTX) Given "Buy" Rating at HC Wainwright
October 5, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31086559
Elon just declared war on your phone
SpaceX reportedly agreed to pay 8 billion dollars for a major slice of U.S. wireless spectrum, and shares of AT&T, Verizon, and T-Mobile dropped within hours of the news. Elon Musk called the deal the last critical piece for complete phone coverage in America, fueling speculation about a future device that could challenge the iPhone.tc pixel
 |  Stansberry Research (Ad)
Analysts’ Opinions Are Mixed on These Healthcare Stocks: MoonLake Immunotherapeutics (MLTX) and Liquidia Technologies (LQDA)
October 2, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/LQDA/pressreleases/4918204/analysts-opinions-are-mixed-on-these-healthcare-stocks-moonlake-immunotherapeutics-mltx-and-liquidia-technologies-lqda/
MoonLake files FDA application for sonelokimab therapy
September 30, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/moonlake-files-fda-application-for-sonelokimab-therapy?utm_source=marketbeat.com&utm_medium=referral
MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Now Rated "Moderate Buy" by Wall Street Analysts
September 29, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31062231
See More MoonLake Immunotherapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like MoonLake Immunotherapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on MoonLake Immunotherapeutics and other key companies, straight to your email.

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics (NASDAQ:MLTX) is a clinical-stage biopharmaceutical company focused on developing medicines for inflammatory and immunologic diseases. The company is headquartered in Zug, Switzerland, and its ordinary shares trade on the Nasdaq under the symbol MLTX.

MoonLake’s primary product candidate is sonelokimab, a novel Nanobody-based inhibitor designed to selectively target interleukin-17A and interleukin-17F, two cytokines involved in inflammation. The company is evaluating sonelokimab in conditions including hidradenitis suppurativa, psoriatic arthritis and axial spondyloarthritis, with the goal of addressing significant unmet needs in chronic inflammatory disease.

MoonLake was established to advance sonelokimab and related immunology programs and has developed its business around a Nanobody-based drug-development platform. The company’s activities are focused primarily on clinical development and regulatory preparation rather than commercialized products, and its programs are intended for patients in international markets where inflammatory diseases are prevalent.

View MoonLake Immunotherapeutics Profile
Earnings Tools